APC
IOVA icon

Aspire Private Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Aspire Private Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-108
Closed -$3K – 504
2019
Q2 		$3K Buy
+108
New +$1.63K ﹤0.01% 362

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Aspire Private Capital's IOVA Position: Q3 2019 in Review

Aspire Private Capital sold out of Iovance Biotherapeutics (IOVA) in Q3 2019, closing a stake of 108 shares — an estimated $3K sold.

Aspire Private Capital first reported a position in IOVA in Q2 2019 and held it in 1 quarter. The position peaked at $3K in Q2 2019. 173 funds tracked by Wall St. Rank hold IOVA as of Q3 2019.

  • Aspire Private Capital reported no remaining Iovance Biotherapeutics position as of Q3 2019 after selling out during the quarter.
  • Aspire Private Capital sold 108 Iovance Biotherapeutics shares in Q3 2019, an estimated $3K.
  • Aspire Private Capital first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 1 quarter.
  • Aspire Private Capital's Iovance Biotherapeutics position peaked at $3K in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2019.

Based on Aspire Private Capital's 13F filing for Q3 2019, filed 12 Nov 2019.